Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents - minimum inhibitory concentration versus time-kill curves

被引:19
作者
Schmidt, Stephan [1 ]
Schuck, Edgar [1 ]
Kumar, Vipul [1 ]
Burkhardt, Olaf [1 ,2 ]
Derendorf, Hartmut [1 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[2] Hannover Med Sch, Dept Pulm Med, D-3000 Hannover, Germany
关键词
EC50; MIC; PK/PD modeling; time-kill curves;
D O I
10.1517/17460441.2.6.849
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The selection of appropriate doses and dosing regimens is extremely important in antimicrobial therapy in order to increase the chances of clinical success and decrease the likelihood of toxic side effects and the development of resistance. Therefore, empirical treatment of bacterial infections is not reliable enough and more rational approaches are needed. Pharmacokinetic/pharmacodynamic (PK/PD) modeling provides a powerful tool to systematically link PK and PD properties in order to predict antimicrobial efficacy. However, commonly used minimum inhibitory concentration (MIC) based PK/PD indices, although easy to obtain, have a number of limitations. Thus, more reliable PK/PD indices need to be developed. The following article provides an overview of the present PK/PD approaches used in anti-infective therapy and discusses their role in improving drug therapy.
引用
收藏
页码:849 / 860
页数:12
相关论文
共 104 条
[41]  
JACOBS MR, 2003, INT J INFECT DIS, V7, P13
[42]   Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria [J].
Kashuba, ADM ;
Nafziger, AN ;
Drusano, GL ;
Bertino, JS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :623-629
[43]  
KHUNVICHAI AHM, 2001, PNEUM HAEM INFL 41 A
[44]  
KHUNVICHAI AKM, 2003, 32 ANN M AM COLL CLI
[45]  
Klugman Keith P., 2003, International Journal of Infectious Diseases, V7, pS27, DOI 10.1016/S1201-9712(03)90068-3
[46]   Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa [J].
Kuti, JL ;
Florea, NR ;
Nightingale, CH ;
Nicolau, DP .
PHARMACOTHERAPY, 2004, 24 (01) :8-15
[47]   Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem [J].
Kuti, JL ;
Dandekar, PK ;
Nightingale, CH ;
Nicolau, DP .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (10) :1116-1123
[48]   Rational dosing of antimicrobial drugs: animals versus humans [J].
Lees, P ;
Aliabadi, FS .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :269-284
[49]   Opinion - Non-inherited antibiotic resistance [J].
Levin, Bruce R. ;
Rozen, Daniel E. .
NATURE REVIEWS MICROBIOLOGY, 2006, 4 (07) :556-562
[50]   Achieving an optimal outcome in the treatment of infections - The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials [J].
Li, RC ;
Zhu, M ;
Schentag, JJ .
CLINICAL PHARMACOKINETICS, 1999, 37 (01) :1-16